Implications for the assay and biological activity of interleukin-4. Results of a WHO international collaborative study

Journal of Immunological Methods

Volumn 194, Issue 1, 1996, Pages 13-25

  Mire Sluis, Anthony R ^a   Das, Rose Gaines ^a   Thorpe, Robin ^a   Thomas, Sandra ^b   Maher, Darryl ^c   Valent, Peter ^d   Payer, Elisabeth ^d   De Groote, ^e   Hayglass, Kent ^f   Ziltener, H ^g   Poulsen, Lars K ^h   Miossec, Pierre ⁱ   Chomarat, P ⁱ   Grassi, Jacques ^j   Pawelec, G ^k   Fritzsche, U ^l   Falk, M ^m   Topp, M ⁿ   Reisbach, G ^o   Sidiropoulos, John ^p   Ben Sasson, S Z ^q   Even Chen, Zeev ^r   Pegoraro, Luigi ^s   Barboni, Francesco ^t   Sugimoto, Kenkichi ^u   Tsuji, K ^v   Matsumoto, Tomoaki ^w   Arai, Kenrichi ^x   Yokota, Takashi ^x   Olobo, J ^y   Wagemaker, G ^z   Van Der Pouw Kraan, T ^aa   Sheth, Kirrikant V ^ab   Gutierrez, C ^ac   Rivas, D ^ac   Lyeke, Nils ^ad   Schön, Karin ^ad   Bews, John P A ^ae   Tullberg, K ^af   Klotzbucher R ^ag   Page, L ^a   Bird, C ^a   McGuckin, Colin P ^ah   Gordon, John ^ai   Katira, Anita ^ai   Openshaw, Peter ^aj   Georgiou, Andrew ^aj   Testa, Nydia G ^ak   Callard, Robin ^al   Paik, K ^am   McKearn, John ^am   Rock, Marie ^am   Harper, Kathleen ^am   Swanson, Steven J ^an   Siegel, Jay P ^ao   Spiegelberg, H L ^ap   Geigert, John ^aq   Carter, Kerri ^aq   Paul, William E ^ar   Watson, Cynthia ^ar   Tsang, Monica ^as   Zhou, Li ^as   Westreich, Louis ^an   Chao, Chun C ^at   Riss, Terry L ^au   Moravec, Rich ^au   more..

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Zoning Industrial   (Belgium)

^f UNIVERSITY OF MANITOBA   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Rigshospitalet   (Denmark)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j DIF   (France)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l Behringwerke AG   (Germany)

^m Department of Cell Biology   (Germany)

ⁿ FREIE UNIVERSITÄT BERLIN   (Germany)

^o INSTITUTE OF EPIDEMIOLOGY   (Germany)

^p Aristotle University of Thessaloniki   (Greece)

^q HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^r Israel Chemicals Ltd   (Israel)

^s Sezione Clinica   (Italy)

^t Malpighi Hospital   (Italy)

^u NIIGATA UNIVERSITY   (Japan)

^v SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^w KUMAMOTO UNIVERSITY   (Japan)

^x UNIVERSITY OF TOKYO   (Japan)

^y INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^z ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^aa CENTRAL LABORATORY   (Netherlands)

^ab KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^ac HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^ad UNIVERSITY OF GOTHENBURG   (Sweden)

^ae CIBA GEIGY LTD   (Switzerland)

^af Sandoz Pharma Ltd   (Switzerland)

^ag F HOFFMANN LA ROCHE LTD   (Switzerland)

^ah ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^ai UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^aj IMPERIAL COLLEGE LONDON   (United Kingdom)

^ak CHRISTIE HOSPITAL   (United Kingdom)

^al UNIVERSITY COLLEGE LONDON   (United Kingdom)

^am PFIZER INC   (United States)

^an MERCK RESEARCH LABORATORIES   (United States)

^ao CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^ap UNIVERSITY OF CALIFORNIA   (United States)

^aq AMGEN INC   (United States)

^ar NATIONAL INSTITUTES OF HEALTH   (United States)

^as R and D Systems Inc   (United States)

^at MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^au PROMEGA CORPORATION   (United States)

more..

Author keywords

IL 4; Standardization

Indexed keywords

CYTOKINE; INTERLEUKIN 3; INTERLEUKIN 4; RECOMBINANT DNA; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 4;

ARTICLE; BIOASSAY; BONE MARROW CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INTERNATIONAL COOPERATION; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STANDARD; WORLD HEALTH ORGANIZATION;

EID: 0030591585     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-1759(96)00069-5     Document Type: Article

References (13)

1. Avanzi, G.C., Lista, P., Giovinazzo, B., Miniero, R., Saglio, G., Benetton, G., Coda, R., Cattoretti, G. and Pegoraro, L. (1988) Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br. J. Haematol. 69, 356.
2. Defrance, T., Fluckiger, A.C., Rossi, J.F., Magaud, J.P., Sotto, J.J. and Banchereau, J. (1992) Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. Blood 79, 990.
3. Gilleece, M.H., Scarffe, J.H., Ghosh, A., Heyworth, C.M., Bonnem, E., Testa, N., Stern, P. and Dexter, T.M. (1992) Recombinant human interleukin-4 (IL-4) given as daily subcutaneous injections - A phase I dose toxicity trial. Br. J. Cancer 66, 204.
4. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M. and Pardoll, D.M. (1991) Treatment of established renal cancer by tumour cells engineered to secrete interleukin-4. Science 254, 713.
5. Howard, M., Farrar, J., Hilfiker, M., Johnson, B., Takatsu, K., Hamaoka, T. and Paul, W.E. (1982) Identification of a T cell derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 155, 914.
6. Margolin, K., Aronson, F.R., Sznol, M., Atkins, M.B., Gucalp, R., Fisher, R.I., Sunderland, M., Doroshow, J.H., Ernest, M.L. and Mier, J.W. (1994) Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother. Emphasis Tumor Immunol. 15, 147.
7. Ohara, J., Coligan, J., Zoon, K., Maloy, W.L. and Paul, W.E. (1987) High-efficiency purification and chemical characterization of B cell stimulatory factor-1/interleukin-4. J. Immunol. 139, 1127.
8. Ohura, J. (1988) Interleukin-4: Molecular structure and biochemical characteristics, biological function, and receptor expression. Year Immunol. 5, 126.
9. Siegel, J.P. and Mostowski, H.S. (1990) A bioassay for the measurement of human interleukin-4. J. Immunol. Methods 132, 287.
10. Toi, M., Bicknell, R. and Harris, A.L. (1992) Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52, 275.
11. Topp, M.S., Koenigsmann, M., Mire-Sluis, A., Oberberg, D., Eitelbach, F., Marschall, Z. von, Notter, M., Reufi, B., Stein, H., Thiel, E. and Berdel, W.E. (1993) Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 82, 2837.
12. Yokota, T., Otsuka, T., Mosmann, T., Banchereau, J., Defrance, T., Blanchard, D., de Vries, J.E., Lee, F. and Arai, K. (1986) Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor-1, that expresses B-cell-and T-cell-stimulatory activities. Proc. Natl. Acad. Sci. USA 83, 5894.
13. Yokota, T., Arai, N., DeVries, J., Spitz, H., Banchereau, J., Zlotnick, A., Rennick, D., Howard, M., Takebe, Y., Miyatakes, L.F. and Arai, F. (1988) Molecular biology of interleukin-4 and interleukin-5 genes and biology of the product that stimulate B cells. T cells and hematopoietic cells. Immunol. Rev. 102, 172.